Accelerated waning of the humoral response to COVID-19 vaccines in obesity

[1]  M. Linterman,et al.  Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination , 2022, Cell Reports Medicine.

[2]  K. Khunti,et al.  A retrospective cohort study predicting and validating impact of the COVID-19 pandemic in individuals with chronic kidney disease , 2022, Kidney International.

[3]  P. Simmonds,et al.  Convalescent plasma donors show enhanced cross‐reactive neutralizing antibody response to antigenic variants of SARS‐CoV‐2 following immunization , 2022, Transfusion.

[4]  K. Miyo,et al.  Sex‐associated differences between BMI and SARS‐CoV‐2 antibody titers following the BNT162b2 vaccine , 2022, Obesity.

[5]  P. Diggle,et al.  Population antibody responses following COVID-19 vaccination in 212,102 individuals , 2022, Nature communications.

[6]  Prem R. Warde,et al.  Real world SARS-COV-2 vaccine effectiveness in a Miami academic institution , 2022, The American Journal of Emergency Medicine.

[7]  Frances E. Muldoon,et al.  Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity , 2022, Nature.

[8]  Colin Simpson,et al.  Investigating the uptake, effectiveness and safety of COVID-19 vaccines: protocol for an observational study using linked UK national data , 2022, BMJ Open.

[9]  M. Dimopoulos,et al.  Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis , 2022, Biomedicines.

[10]  C. Knabbe,et al.  Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study , 2021, Frontiers in Immunology.

[11]  R. Arbel,et al.  BNT162b2 Vaccine Booster and Mortality Due to Covid-19 , 2021, The New England journal of medicine.

[12]  Anna V. Protasio,et al.  A protease-activatable luminescent biosensor and reporter cell line for authentic SARS-CoV-2 infection , 2021, bioRxiv.

[13]  Lindsay N. Carpp,et al.  Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.

[14]  Colin Simpson,et al.  External validation of the QCovid risk prediction algorithm for risk of COVID-19 hospitalisation and mortality in adults: national validation cohort study in Scotland , 2021, Thorax.

[15]  Fatima Cody Stanford,et al.  A long shot: The importance of needle length in vaccinating patients with obesity against COVID-19 , 2021, Vaccine.

[16]  P. Klenerman,et al.  T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study , 2021, The Lancet Microbe.

[17]  G. Mattiuzzo,et al.  WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community , 2021, The Lancet Microbe.

[18]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[19]  Kenneth G. C. Smith,et al.  Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease , 2021, Immunity.

[20]  S. O’Rahilly,et al.  Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study , 2021, The Lancet Diabetes & Endocrinology.

[21]  Colin Simpson,et al.  Cohort profile: Early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database , 2021, International journal of epidemiology.

[22]  Ravindra K. Gupta,et al.  The effect of spike mutations on SARS-CoV-2 neutralization , 2021, Cell Reports.

[23]  A. Wheatley,et al.  The memory B cell response to influenza vaccination is impaired in older persons , 2021, bioRxiv.

[24]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[25]  A. Iafrate,et al.  COVID-19-neutralizing antibodies predict disease severity and survival , 2020, Cell.

[26]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[27]  A. Liston,et al.  A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice , 2020, bioRxiv.

[28]  Benjamin S. Glicksberg,et al.  Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19 , 2020, Journal of the American College of Cardiology.

[29]  B. Popkin,et al.  Individuals with obesity and COVID‐19: A global perspective on the epidemiology and biological relationships , 2020, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[30]  T. Solomon,et al.  Methods of Inactivation of SARS-CoV-2 for Downstream Biological Assays , 2020, The Journal of infectious diseases.

[31]  K. Khunti,et al.  Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study , 2020, The Lancet Diabetes & Endocrinology.

[32]  Carly E. Whyte,et al.  Microglia Require CD4 T Cells to Complete the Fetal-to-Adult Transition , 2020, Cell.

[33]  John A.G. Briggs,et al.  A thermostable, closed SARS-CoV-2 spike protein trimer , 2020, Nature Structural & Molecular Biology.

[34]  D. Matthews,et al.  Neuropilin-1 is a host factor for SARS-CoV-2 infection , 2020, Science.

[35]  Colin Simpson,et al.  Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data , 2020, BMJ Open.

[36]  S. Merler,et al.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.

[37]  M. Cancro.  Age-Associated B Cells. , 2020, Annual review of immunology.

[38]  F. Spertini,et al.  The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRβ clonotypes , 2019, The Journal of experimental medicine.

[39]  M. Hudgens,et al.  Increased risk of influenza among vaccinated adults who are obese , 2017, International Journal of Obesity.

[40]  G. Poland,et al.  The weight of obesity on the human immune response to vaccination. , 2015, Vaccine.

[41]  Tormod Fladby,et al.  A Practical Guide to Immunoassay Method Validation , 2015, Front. Neurol..

[42]  K. Rosenman,et al.  Incidence and variables associated with inadequate antibody titers after pre-exposure rabies vaccination among veterinary medical students. , 2014, Vaccine.

[43]  M. Hudgens,et al.  Obesity is associated with impaired immune response to influenza vaccination in humans , 2011, International Journal of Obesity.

[44]  A. Eliakim,et al.  Reduced tetanus antibody titers in overweight children , 2006 .